BHI was numerically highest in the natalizumab group (first-line: 0.860 ± 0.135; natalizumab: 0.936 ± 0.124; anti-CD20: 0.862 ± 0.118), but the overall between-group difference did not reach statistical significance (Welch’s F [2, 47.89] = 3.045, p = 0.057).
← all excerpts
Impaired cerebrovascular reactivity is associated with disability and cognitive performance in relapsing-remitting multiple sclerosis.
1
0.0570
0.0570